Breast Cancer Response Before Surgery Matters (CME/CE)
SAN ANTONIO (MedPage Today) -- Complete pathologic responses seen with neoadjuvant trastuzumab (Herceptin) and lapatinib (Tykerb) among breast cancer patients correlated with better survival, according to a clinical trial subanalysis.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Herceptin | Neoadjuvant Therapy